# Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

> **NCT05081193** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 15 (actual)

## Conditions studied

- Prostate Cancer
- Castration-resistant Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Testosterone Undecanoate
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT05081193
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-07
- **Primary completion:** 2025-08-04
- **Final completion:** 2025-08-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05081193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05081193, "Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05081193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*